Larimar Beats Q2 Loss Estimates
Larimar Therapeutics ( NASDAQ:LRMR ) , a clinical-stage biotechnology firm focused on treatments for rare diseases such as Friedreich's ataxia, reported its second quarter results on August 14, 2025. The key news was a net loss per share ( GAAP ) of $0.41 in Q2 2025, which was smaller than the ...
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
BALA CYNWYD, Pa., July 31, 2025 ( GLOBE NEWSWIRE ) -- Larimar Therapeutics, Inc. ( "Larimar" ) ( Nasdaq: LRMR ) , a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten public ...
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares - Larimar Therapeutics ( NASDAQ:LRMR )
BALA CYNWYD, Pa., July 31, 2025 ( GLOBE NEWSWIRE ) -- Larimar Therapeutics, Inc. ( "Larimar" ) LRMR, a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten public offering of ...
Larimar Therapeutics Announces Pricing of Underwritten Public Offering
BALA CYNWYD, Pa., July 29, 2025 ( GLOBE NEWSWIRE ) -- Larimar Therapeutics, Inc. ( "Larimar" ) ( Nasdaq: LRMR ) , a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its previously announced underwritten public ...
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
CPRX, ZVRA, TBPH, ALDX, and LRMR shine amid tariff threats, thanks to strong pipelines, demand, and rising earnings estimates.
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia
Conference call and webcast on Monday, June 23, 2025 at 8:00 am EDT Conference call and webcast on Monday, June 23, 2025 at 8:00 am ...
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results
BALA CYNWYD, Pa., March 24, 2025 ( GLOBE NEWSWIRE ) -- Larimar Therapeutics, Inc. ( Larimar ) ( Nasdaq: LRMR ) , a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2024 operating and financial results.
This MicroStrategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Datadog ( NASDAQ:DDOG ) , Curbline Properties ( NYSE:CURB )
Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Morgan Stanley analyst Cesar Medina initiated coverage on Millicom International Cellular S.A.
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia - Larimar Therapeutics ( NASDAQ:LRMR )
Adolescents receive a weight-based dose equivalent to the 50 mg adult dose Adolescents 12-17 years old who complete participation in the pharmacokinetic ( PK ) run-in study will be eligible to screen in the ongoing open label extension ( OLE ) study
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes
Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board ...
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes - Spero Therapeutics ( NASDAQ:SPRO )
Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company's Response to a Wells Notice from the SEC Relating to Certain Public Disclosures Made in 2022
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia
Solid Biosciences rises as the FDA clears SGT-212, a gene therapy candidate, for clinical studies for the treatment of Friedreich's ataxia.
What's Going On With Larimar Therapeutics Stock On Tuesday? - Larimar Therapeutics ( NASDAQ:LRMR )
Tissue FXN levels showed significant increase, with 25 mg nomlabofusp achieving 30% of healthy volunteers' levels in buccal cells by Day 90. William Blair expects positive dose escalation to 50 mg, predicting FXN levels to reach 30% of normal levels in ~90% of patients.
Crude Oil Down 1%; Webuy Global Shares Spike Higher - Akso Health ( NASDAQ:AHG ) , Akoustis Technologies ( NASDAQ:AKTS )
U.S. stocks traded mostly higher midway through trading, with the S&P 500 gaining around 0.4% on Monday. The Dow traded down 0.08% to 43,794.43 while the NASDAQ rose 0.91% to 20,107.71. The S&P 500 also rose, gaining, 0.37% to 6,073.33. Communication services shares jumped by 1.6% on Monday.
Why Is Larimar Therapeutics Stock Trading Lower On Monday? - Larimar Therapeutics ( NASDAQ:LRMR )
Tissue FXN levels increased from 15% to 30% in buccal cells and 16% to 72% in skin cells after 90 days of daily 25 mg nomlabofusp. Nomlabofusp was well tolerated; most adverse events were mild and resolved quickly, with dose escalation to 50 mg underway. On Monday, Larimar Therapeutics, Inc.
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia
BALA CYNWYD, Pa., Dec. 16, 2024 ( GLOBE NEWSWIRE ) -- Larimar Therapeutics, Inc. ( Larimar ) ( Nasdaq: LRMR ) , a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced positive initial data from the ongoing long-term OLE study evaluating ...
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.
Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock - Larimar Therapeutics ( NASDAQ:LRMR )
Oppenheimer has initiated coverage on Larimar Therapeutics LRMR, a clinical-stage biotechnology company focused on developing treatments for rare diseases.
Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research
BALA CYNWYD, Pa., Sept. 19, 2024 ( GLOBE NEWSWIRE ) -- Larimar Therapeutics, Inc. ( Larimar ) ( Nasdaq: LRMR ) , a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company's nomlabofusp Phase 1 studies and Phase 2 ...
G-III Apparel Posts Upbeat Results, Joins NIO, Yext, Shoe Carnival And Other Big Stocks Moving Higher On Thursday - G-III Apparel Group ( NASDAQ:GIII )
U.S. stocks were mostly lower, with the Dow Jones index falling around 300 points on Thursday. Shares of G-III Apparel Group, Ltd. GIII rose sharply during Thursday's session after the company reported better-than-expected second-quarter adjusted EPS results and issued its FY25 guidance above ...
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday - NVIDIA ( NASDAQ:NVDA )
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. Shares of NVIDIA Corporation NVDA rose during Tuesday's session. Keybanc analyst John Vinh maintained NVIDIA with an Overweight and raised the price target from $130 to $180. NVIDIA shares gained 3.5% to ...
Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Aptiv ( NYSE:APTV ) , Trump Media & Technology ( NASDAQ:DJT )
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.2% on Wednesday. Shares of Worthington Enterprises, Inc. WOR fell sharply in today's pre-market trading after the company posted downbeat quarterly results.
AMC Networks, Louisiana-Pacific And Other Big Stocks Moving Lower In Monday's Pre-Market Session - AMC Networks ( NASDAQ:AMCX )
U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Monday. Shares of AMC Networks Inc. AMCX fell sharply in today's pre-market trading after the company announced a private offering of $125 million of convertible senior notes.
Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday - AC Immune ( NASDAQ:ACIU ) , Ambarella ( NASDAQ:AMBA )
U.S. stocks were mixed, with the Nasdaq Composite falling around 1% on Friday. Shares of Ambarella, Inc. AMBA rose sharply during Friday's session following strong first-quarter earnings and upbeat second-quarter guidance.
2 Potentially High-Reward Growth Stocks to Buy Right Now
These two biotechnology stocks could be gearing up for a run.
Hello Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Hello Gr ( NASDAQ:MOMO )
U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining around 0.5% on Tuesday. Shares of Hello Group Inc. MOMO fell sharply in today's pre-market trading following first-quarter results. Hello Group posted adjusted EPADS of 4 cents, compared to market expectations of ...
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics are part of the Zacks top Analyst Blog.
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
Biogen (BIIB) and PTC Therapeutics, Inc. (PTCT) are in the spotlight following acquisition news and regulatory updates, respectively.
Larimar ( LRMR ) Up on Lifting of Partial Clinical Hold on FA Study
The FDA removes the partial clinical hold on Larimar's (LRMR) nomlabofusp clinical program for the treatment of patients with Friedreich's Ataxia.
Larimar Therapeutics' Friedreich's Ataxia Investigational Drug Differentiated From Biogen's Marketed Drug - Larimar Therapeutics ( NASDAQ:LRMR )
On Monday, Larimar Therapeutics Inc LRMR announced that the FDA removed the previous partial clinical hold on -nomlabofusp ( CTI-1601 ) clinical program for Friedreich's Ataxia ( FA ) . Nomlabofusp is a novel protein replacement therapy designed to address the root cause of FA by ...
XPeng Posts Strong Results, Joins Larimar Therapeutics, Transcat And Other Big Stocks Moving Higher On Tuesday - XPeng ( NYSE:XPEV )
U.S. stocks were mostly higher, with the Dow Jones index gaining around 50 points on Tuesday. Shares of XPeng Inc. XPEV rose sharply during Tuesday's session after the company reported better-than-expected first-quarter results and issued second-quarter guidance.
Why Larimar Therapeutics Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Larimar Therapeutics ( NASDAQ:LRMR )
Shares of Larimar Therapeutics, Inc.. LRMR rose sharply in today's pre-market trading after the company announced that the FDA removed the partial clinical hold previously placed on the nomlabofusp clinical program. Larimar Therapeutics shares jumped 17.6% to $8.55 in the pre-market trading session.
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia - Larimar Therapeutics ( NASDAQ:LRMR )
Food and Drug Administration ( FDA ) removed partial clinical hold following review of Phase 2 dose exploration study data Ongoing open label extension ( OLE ) study initially evaluating 25 mg. Larimar plans to dose escalate to 50 mg following further characterization of frataxin ...
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia
BALA CYNWYD, Pa., May 20, 2024 ( GLOBE NEWSWIRE ) -- Larimar Therapeutics, Inc. ( Larimar ) ( Nasdaq: LRMR ) , a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the U.S.
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia - Larimar Therapeutics ( NASDAQ:LRMR )
Study will inform on long-term safety profile and tissue frataxin levels OLE initiated with 25 mg daily subcutaneous injections of nomlabofusp Frataxin data and safety data from the OLE study are intended to help support a potential Biologics License Application ( "BLA" ) submission for ...
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
BALA CYNWYD, Pa., March 06, 2024 ( GLOBE NEWSWIRE ) -- Larimar Therapeutics, Inc. ( "Larimar" ) ( Nasdaq: LRMR ) , a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and ...
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference - Larimar Therapeutics ( NASDAQ:LRMR )
BALA CYNWYD, Pa., March 06, 2024 ( GLOBE NEWSWIRE ) -- Larimar Therapeutics, Inc. ( "Larimar" ) LRMR, a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and participate in ...
Over $37M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying - Agree Realty ( NYSE:ADC ) , Alteryx ( NYSE:AYX )
Although U.S. stocks closed lower on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
BALA CYNWYD, Pa., Feb. 16, 2024 ( GLOBE NEWSWIRE ) -- Larimar Therapeutics, Inc. ( "Larimar" ) ( Nasdaq: LRMR ) , a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten public ...
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares - Larimar Therapeutics ( NASDAQ:LRMR )
BALA CYNWYD, Pa., Feb. 16, 2024 ( GLOBE NEWSWIRE ) -- Larimar Therapeutics, Inc. ( "Larimar" ) LRMR, a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten public offering of ...
Cisco Issues Weak Outlook, Joins Fastly, Herbalife And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Herbalife ( NYSE:HLF ) , Carbon Collective Climate Solutions U.S. Equity ETF ( NASDAQ:CCSO ) , Fastly ( NYSE:FSLY )
U.S. stock futures were higher this morning, with the Dow futures trading higher by around 70 points on Thursday. Shares of Cisco Systems, Inc. CSCO fell in today's pre-market trading following second-quarter results. Cisco reported better-than-expected second-quarter financial results but ...
Charles River Laboratories International Posts Upbeat Results, Joins Robinhood, Zillow, Tower Semiconductor And Other Big Stocks Moving Higher On Wednesday - Zillow Gr ( NASDAQ:Z ) , Charles River ( NYSE:CRL ) , Robinhood Markets ( NASDAQ:HOOD )
U.S. stocks were higher, with the Dow Jones index gaining more than 100 points on Wednesday. Shares of Charles River Laboratories International, Inc. CRL rose sharply during Wednesday's session after the company reported better-than-expected fourth-quarter results and issued guidance above ...
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
BALA CYNWYD, Pa., Feb. 14, 2024 ( GLOBE NEWSWIRE ) -- Larimar Therapeutics, Inc. ( "Larimar" ) ( Nasdaq: LRMR ) , a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its previously announced underwritten public ...
Larimar Therapeutics Announces Proposed Underwritten Public Offering - Larimar Therapeutics ( NASDAQ:LRMR )
BALA CYNWYD, Pa., Feb. 13, 2024 ( GLOBE NEWSWIRE ) -- Larimar Therapeutics, Inc. ( "Larimar" ) LRMR, a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of shares of its common ...
Larimar Therapeutics Announces Proposed Underwritten Public Offering
BALA CYNWYD, Pa., Feb. 13, 2024 ( GLOBE NEWSWIRE ) -- Larimar Therapeutics, Inc. ( "Larimar" ) ( Nasdaq: LRMR ) , a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of shares of ...
Ecolab Posts Strong Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Tuesday - Bruker ( NASDAQ:BRKR ) , Aspen Aerogels ( NYSE:ASPN )
U.S. stocks were lower, with the Dow Jones index dipping more than 500 points on Tuesday. Shares of Ecolab Inc. ECL rose during Tuesday's session after the company reported better-than-expected fourth-quarter financial results and issued first-quarter adjusted EPS guidance above estimates.
Why Is Larimar Therapeutics Stock Trading Lower Today? - Larimar Therapeutics ( NASDAQ:LRMR )
Larimar Therapeutics Inc LRMR released topline data and completed its four-week, placebo-controlled Phase 2 dose exploration study of nomlabofusp ( CTI-1601 ) in participants with Friedreich's ataxia ( FA ) . Friedreich's ataxia is an inherited disorder that affects some of the body's ...
Monday.com Reports Q4 Results, Joins AN2 TherapeuticsAnd Other Big Stocks Moving Lower In Monday's Pre-Market Session - Monday.Com ( NASDAQ:MNDY )
U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 45 points on Monday. Shares of monday.com Ltd. MNDY fell sharply in today's pre-market trading after the company reported fourth-quarter financial results.
